A Phase 2/3 interventional study of MP-214 3mg and MP-214 6mg in Schizophrenia, sponsored by Tanabe Pharma Corporation. Completed at 3 sites in 3 countries. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-01-05.
Sponsored by Tanabe Pharma Corporation · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.
Among the 23 studies testing cariprazine in Schizophrenia, this one is the 6th largest by enrollment, is one of 5 that started in 2012, is one of 6 in phase 2/3, and was the 10th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:
Mapi Pharma Ltd. · Sites in India, Israel
Ages 18–64
Gedeon Richter Plc. · Sites in United States, Bulgaria, Colombia and 5 more countries
Ages 13–17
New York State Psychiatric Institute
Ages 18–55
Bostal Drug Delivery Co., Ltd
Ages 18–65
By country, each count listing its studies:
cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 20 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 14
First in 2006; this study’s year is marked. 5 started in 2012.
This study's enrollment of 512 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 129 across the 23 interventional studies. Of the 18 that completed or were terminated, 14 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 23 have an industry lead sponsor. The 10 most frequent:
Tanabe Pharma Corporation is the lead sponsor of 92 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Tanabe Pharma Corporation has 6 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
3 of the studies testing cariprazine in Schizophrenia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03817502Phase 3Gedeon Richter Plc.Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | 2026-12-15 |
| NCT07722728Phase 3Bostal Drug Delivery Co., LtdA Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia | 2027-08 |
| NCT07185815Mapi Pharma Ltd.Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies testing cariprazine in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the efficacy, safety, and tolerability of MP-214 relative to placebo in patients with acute exacerbation of schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MP-214 3mg
Drug: MP-214 6mg
Drug: MP-214 9mg
Drug: Risperidone 4mg
Drug: Placebo
Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.
Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.
Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.
Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.
Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.
Change in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6
PANSS score is a 30-item rating scale to assess both the positive and negative symptom syndromes of patients with schizophrenia. Each item is scored on a 7-point scale, from 1 (absent) to 7 (extreme). The PANSS total score of the 30 PANSS items ranges from 30 to 210. High scores indicate greater severity of symptoms.
Time frame: Baseline and Week 6
Change in the Clinical Global Impression-Severity (CGI-S) Score at Week 6
CGI-S is a 7-point scale to assess the global severity of the participant's illness. CGI-S scores range from 1 (normal, not ill at all) to 7 (extremely ill).
Time frame: Baseline and Week 6
| Milestone | MP-214 3mg | MP-214 6mg | MP-214 9mg | Risperidone 4mg | Placebo |
|---|---|---|---|---|---|
| Started | 126 | 133 | 67 | 56 | 126 |
| Completed | 74 | 81 | 34 | 37 | 71 |
| Not completed | 52 | 52 | 33 | 19 | 55 |
| Withdrew: Physician decision | 15 | 7 | 7 | 2 | 15 |
| Withdrew: Protocol violation | 3 | 10 | 4 | 1 | 2 |
| Withdrew: Withdrawal by subject | 19 | 16 | 11 | 9 | 17 |
| Withdrew: Adverse event (including death) | 15 | 19 | 11 | 7 | 21 |
PANSS score is a 30-item rating scale to assess both the positive and negative symptom syndromes of patients with schizophrenia. Each item is scored on a 7-point scale, from 1 (absent) to 7 (extreme). The PANSS total score of the 30 PANSS items ranges from 30 to 210. High scores indicate greater severity of symptoms.
| units on a scale | MP-214 3mg | MP-214 6mg | MP-214 9mg | Risperidone 4mg | Placebo |
|---|---|---|---|---|---|
| Change in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 | -10.4 ± 2.0 | -13.8 ± 2.0 | -14.0 ± 2.9 | -20.2 ± 3.0 | -9.5 ± 2.1 |
CGI-S is a 7-point scale to assess the global severity of the participant's illness. CGI-S scores range from 1 (normal, not ill at all) to 7 (extremely ill).
| units on a scale | MP-214 3mg | MP-214 6mg | MP-214 9mg | Risperidone 4mg | Placebo |
|---|---|---|---|---|---|
| Change in the Clinical Global Impression-Severity (CGI-S) Score at Week 6 | -0.7 ± 0.1 | -0.8 ± 0.1 | -0.7 ± 0.2 | -1.2 ± 0.2 | -0.6 ± 0.1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MP-214 3mg | — | 12/126 (9.5%) | 95/126 (75.4%) |
| MP-214 6mg | — | 16/133 (12%) | 100/133 (75.2%) |
| MP-214 9mg | — | 4/67 (6%) | 52/67 (77.6%) |
| Risperidone 4mg | — | 2/56 (3.6%) | 36/56 (64.3%) |
| Placebo | — | 14/126 (11.1%) | 72/126 (57.1%) |
| Event | MP-214 3mg | MP-214 6mg | MP-214 9mg | Risperidone 4mg | Placebo |
|---|---|---|---|---|---|
| SchizophreniaPsychiatric disorders | 9/126 | 14/133 | 3/67 | 0/56 | 12/126 |
| AkathisiaNervous system disorders | 0/126 | 0/133 | 0/67 | 1/56 | 0/126 |
| Extrapyramidal disorderNervous system disorders | 0/126 | 0/133 | 0/67 | 1/56 | 0/126 |
| Suicide attemptPsychiatric disorders | 1/126 | 0/133 | 0/67 | 1/56 | 1/126 |
| AgitationPsychiatric disorders | 0/126 | 0/133 | 1/67 | 0/56 | 0/126 |
| Suicidal behaviourPsychiatric disorders | 0/126 | 0/133 | 1/67 | 0/56 | 0/126 |
| Suicidal ideationPsychiatric disorders | 0/126 | 0/133 | 1/67 | 0/56 | 0/126 |
| Infection maskedInfections and infestations | 0/126 | 0/133 | 0/67 | 0/56 | 1/126 |
| PneumoniaInfections and infestations | 1/126 | 0/133 | 0/67 | 0/56 | 0/126 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/126 | 0/133 | 0/67 | 0/56 | 0/126 |
| Event | MP-214 3mg | MP-214 6mg | MP-214 9mg | Risperidone 4mg | Placebo |
|---|---|---|---|---|---|
| AkathisiaNervous system disorders | 28/126 | 19/133 | 2/67 | 9/56 | 10/126 |
| SchizophreniaPsychiatric disorders | 16/126 | 15/133 | 13/67 | 7/56 | 23/126 |
| ConstipationGastrointestinal disorders | 21/126 | 20/133 | 12/67 | 5/56 | 15/126 |
| Extrapyramidal disorderNervous system disorders | 11/126 | 19/133 | 11/67 | 6/56 | 12/126 |
| HeadacheNervous system disorders | 19/126 | 14/133 | 7/67 | 4/56 | 14/126 |
| VomitingGastrointestinal disorders | 18/126 | 12/133 | 5/67 | 1/56 | 7/126 |
| NasopharyngitisInfections and infestations | 10/126 | 15/133 | 9/67 | 8/56 | 6/126 |
| InsomniaPsychiatric disorders | 12/126 | 16/133 | 5/67 | 2/56 | 9/126 |
| NauseaGastrointestinal disorders | 15/126 | 9/133 | 7/67 | 4/56 | 5/126 |
| TremorNervous system disorders | 7/126 | 13/133 | 1/67 | 0/56 | 4/126 |
| Age, Continuous(years) | MP-214 3mg | MP-214 6mg | MP-214 9mg | Risperidone 4mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 40.6 ± 10.6 | 40.2 ± 11.4 | 43.0 ± 9.7 | 39.5 ± 10.2 | 40.1 ± 11.1 | 40.6 ± 10.8 |
| Sex: Female, Male(Participants) | MP-214 3mg | MP-214 6mg | MP-214 9mg | Risperidone 4mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 60 | 60 | 34 | 25 | 66 | 245 |
| Male | 66 | 73 | 33 | 31 | 60 | 263 |
The record gives a start of May 2012, a primary completion of Aug 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2021, 5 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine